Literature DB >> 22554159

Antimicrobial use in a critical care unit: a prospective observational study.

Christina L Candeloro1, Lynne M Kelly, Elke Bohdanowicz, Claudio M Martin, Anne Marie Bombassaro.   

Abstract

OBJECTIVE: The purpose of this study was to describe antimicrobial utilization, consumption, indications and microbial resistance in a medical-surgical-trauma intensive care unit (ICU) of a teaching hospital to identify potential targets for antimicrobial stewardship.
METHODS: This was a 30-day prospective observational study enrolling adults admitted to the ICU for at least 24 h and having received antimicrobial therapy. Primary endpoints included utilization as percentage use of antimicrobials by class and agent, consumption measured as days of therapy per 1000 patient days (DOT/1000PD), indications for use and prescriber. Secondary endpoints included reasons for modifications to therapy and microbial resistance. KEY
FINDINGS: Eighty-three patients were screened and 61 enrolled, receiving 133 courses of antimicrobial therapy, mainly intravenously and prescribed by ICU staff. The most frequently prescribed agents were piperacillin/tazobactam (20%), cefazolin (17%) and vancomycin (13%). The indications for therapy were empirical (50%), directed (27%) and prophylactic (23%). Overall consumption was 1368.54 DOT/1000PD and was mainly attributed to empirical therapy (734.25). Prolonged durations were noted for carbapenems and for surgical prophylaxis. There were 86 therapy modifications involving indication (36), efficacy (25), safety (18) and route (7). Suboptimal or excessive dosing were common contributors to efficacy and safety modifications, respectively. Infections due to microorganisms with notable resistance included methicillin-resistant Staphylococcus aureus (5), Pseudomonas aeruginosa (1) and Streptococcus pneumoniae (1).
CONCLUSIONS: Antimicrobial utilization and consumption based on DOT/1000PD were prospectively determined providing a comparator for other ICUs. Potential targets identified for antimicrobial stewardship initiatives include empirical therapy, treatment duration, dosing and route.
© 2011 The Authors. IJPP © 2011 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22554159     DOI: 10.1111/j.2042-7174.2011.00176.x

Source DB:  PubMed          Journal:  Int J Pharm Pract        ISSN: 0961-7671


  6 in total

1.  Appropriateness of gram-negative agent use at a tertiary care hospital in the setting of significant antimicrobial resistance.

Authors:  Neil M Vora; Christine J Kubin; E Yoko Furuya
Journal:  Open Forum Infect Dis       Date:  2015-02-19       Impact factor: 3.835

2.  Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study.

Authors:  V Bakke; H Sporsem; E Von der Lippe; I Nordøy; Y Lao; H C Nyrerød; L Sandvik; K R Hårvig; J F Bugge; E Helset
Journal:  Acta Anaesthesiol Scand       Date:  2017-04-25       Impact factor: 2.105

3.  Assessing the Effectiveness of Antibiotic Therapy Against Common Gram-Negative Bacteria in a Saudi Arabian Hospital Using the Drug Resistance Index.

Authors:  Muhammad Yaseen; Abdulhakeem Althaqafi; Fayssal Farahat; Asim Alsaedi; Abdulfattah Mowallad; Eili Klein; Katie Tseng; Sabiha Essack
Journal:  Cureus       Date:  2022-02-13

4.  Measurement of adult antimicrobial drug use in tertiary care hospital using defined daily dose and days of therapy.

Authors:  Dipika Bansal; S Mangla; K Undela; K Gudala; S D'Cruz; A Sachdev; P Tiwari
Journal:  Indian J Pharm Sci       Date:  2014-05       Impact factor: 0.975

5.  Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study.

Authors:  Hanan H Balkhy; Aiman El-Saed; Ashraf El-Metwally; Yaseen M Arabi; Sameera M Aljohany; Muayed Al Zaibag; Salim Baharoon; Adel F Alothman
Journal:  Antimicrob Resist Infect Control       Date:  2018-12-21       Impact factor: 4.887

6.  An evaluation on the association of vancomycin trough concentration with mortality in critically ill patients: A multicenter retrospective study.

Authors:  Jiajia Ren; Yanli Hou; Jiamei Li; Ya Gao; Ruohan Li; Xuting Jin; Jingjing Zhang; Xiaochuang Wang; Gang Wang
Journal:  Clin Transl Sci       Date:  2021-04-09       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.